Literature DB >> 27123036

Identification of "Multiple Components-Multiple Targets-Multiple Pathways" Associated with Naoxintong Capsule in the Treatment of Heart Diseases Using UPLC/Q-TOF-MS and Network Pharmacology.

Xianghui Ma1, Bin Lv1, Pan Li1, Xiaoqing Jiang1, Qian Zhou1, Xiaoying Wang2, Xiumei Gao1.   

Abstract

Naoxintong capsule (NXT) is a commercial medicinal product approved by the China Food and Drug Administration which is used in the treatment of stroke and coronary heart disease. However, the research on the composition and mechanism of NXT is still lacking. Our research aimed to identify the absorbable components, potential targets, and associated pathways of NXT with network pharmacology method. We explored the chemical compositions of NXT based on UPLC/Q-TOF-MS. Then, we used the five principles of drug absorption to identify absorbable ingredients. The databases of PharmMapper, Universal Protein, and the Molecule Annotation System were used to predict the main targets and related pathways. By the five principles of drug absorption as a judgment rule, we identified 63 compositions that could be absorbed in the blood in all 81 chemical compositions. Based on the constructed networks by the significant regulated 123 targets and 77 pathways, the main components that mediated the efficacy of NXT were organic acids, saponins, and tanshinones. Radix Astragali was the critical herbal medicine in NXT, which contained more active components than other herbs and regulated more targets and pathways. Our results showed that NXT had a therapeutic effect on heart diseases through the pattern "multiple components-multiple targets-multiple pathways."

Entities:  

Year:  2016        PMID: 27123036      PMCID: PMC4830706          DOI: 10.1155/2016/9468087

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


1. Introduction

Naoxintong capsule (NXT) is a commercial medicinal product approved by the China Food and Drug Administration which is widely used in the treatment of stroke and coronary heart disease. NXT contains 16 Chinese herbal medicines (Table 1). NXT exerts significant therapeutic effects and has high safety for stroke recovery in the clinical setting [1]. Recent studies showed that NXT could reduce the infarct size of acute myocardial infarction (AMI) patients by improving vascular endothelial function [2]. Long-term administration of NXT was also reported to alleviate inflammation, reduce the recurrence of angina pectoris, and decrease the incidence of ACS attack in borderline lesion coronary heart disease patients [3]. Some studies investigated the mechanisms of NXT in vitro or in vivo. NXT was reported to protect against atherosclerosis through its lipid-lowering activity [4] and to reduce the expression of iNOS mRNA and the NO level in the vessel wall to benefit the treatment of atherosclerosis [5]. NXT also protected cardiomyoblasts against H2O2-induced oxidative injury [6]. Although some mechanisms of NXT have been reported, existing studies on unilateral factors and single targets could not demonstrate the complex mechanisms of NXT, a herbal prescription with 16 medicines which is prescribed for the treatment of complex diseases like cardiovascular and cerebrovascular diseases.
Table 1

Sixteen Chinese traditional medical herbs of NXT.

AbbreviationMedicinal herbsOriginal plantsContent (g)
RARadix Astragali Astragalus membranaceus (Fisch.) Beg. var. mongholicus (Bge.) Hsiao or A. membranaceus (Fisch.) Bge.66
RPRRadix Paeoniae Rubra Paeonia lactiflora Pall. or P. veitchii Lynch27
RSMRadix Salviae Miltiorrhizae Salvia miltiorrhiza Bge.27
RASRadix Angelicae Sinensis Angelica sinensis (Oliv) Diels. 27
RCXRhizoma Chuanxiong Ligusticum chuanxiong Hort.27
SPSemen Persicae Prunus persica (L.) Batsch or Prunusdavidiana (Carr.) Franch.27
FCFlos Carthami Carthamus tinctorius L.13
FKFrankincense Boswellia carterii Birdw. 13
MRHMyrrha Commiphora myrrha Engl.13
CSCaulis Spatholobi Spatholobus suberectus Dunn20
RABRadix Achyranthis Bidentatae Achyranthes bidentata Bl. or Cyathula officinalis Kuan27
RCRamulus Cinnamomi Cinnamomum cassia Presl20
RMRamulus Mori Morus alba L.27
PTPheretima Pheretima aspergillum (E. Perrier) or Pheretima vulgaris Chen. or Pheretima guillelmi (Michaelsen) or Pheretima pectinifera Michaelsen27
SCPScorpio Buthus martensii Karsch13
HRDHirudo Whitmania pigra Whitman or Hirudo nipponica Whitman or Whitmania acranulata Whitman27

Note. The content of 16 Chinese traditional medical herbs of NXT came from Chinese Pharmacopoeia 2015.

With the prominence of network pharmacology in system biology, this distinct and novel approach to the study of complicated analytical systems is becoming more widely known and more frequently used in the field of drug research. The functions of network pharmacology include uncovering the functions of traditional Chinese medicines (TCMs), providing deeper insights into and scientific evidence for TCMs, and identifying TCMs as scientifically proven. Here, we attempt to explore the mechanism of NXT using this method. In the current study, based on the use of UPLC/Q-TOF-MS to investigate the involved components, we aimed to analyse the absorbable components of NXT, to identify potential targets and associated pathways using the network pharmacology method, and to systematically discuss the mechanism of NXT in the treatment of heart diseases.

2. Material and Methods

2.1. Prediction of Components

2.1.1. Sample Preparation

NXT was obtained from HezeBuchang Pharmaceutical Co., Ltd. (Heze, China). Deionized water was prepared from aqua distillate using a Milli-Q system (Millipore, Bedford, MA, USA). Analytical grade methanol was purchased from Merck (Darmstadt, Germany). We dissolved 1 g of NXT powder in 10 mL of 75% analytical grade methanol and subjected the mixture to ultrasonic extraction for 30 min. We then brought the solution to room temperature and obtained the supernatant as a capture reagent. The sample was filtered using a 0.22 μm microporous membrane before UPLC analysis.

2.1.2. UPLC/Q-TOF-MS

We used a Waters Acquity UPLC System (Waters Co., USA) furnished with a photodiode array detector for the analysis. The sample was diluted on a Waters Acquity UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm). UV detection was achieved at 190–400 nm. The system was controlled using the MassLynx version 4.1 software (Waters Co.). The gradient duration program for A (UPLC-grade acetonitrile) and B (water with 0.1% formic acid) was performed as follows: 2% A from 0 min to 3 min, 10% to 50% A from 3 min to 12 min, 50% to 63% A from 12 min to 18 min, 63% to 83% A from 18 min to 21 min, 83% to 84% A from 21 min to 22 min, 84% to 87% A from 22 min to 26 min, 87% to 90% A from 26 min to 28 min, 90% to 95% A from 28 min to 31 min, 95% to 100% A from 31 to 33 min, 100% to 100% A from 33 to 35 min, and 100% to 2% A from 35 min to 37 min. The flow rate was maintained at 0.4 mL/min, and the column temperature was maintained at 30°C. The components of NXT were identified using a Waters Q-TOF Premier with an electrospray ionization (ESI) system (Waters MS Technologies, Manchester, UK). The ESI-MS spectra were acquired at both negative and positive ion voltages. The capillary voltage was set to 2.5 kV for the negative mode and to 3.0 kV for the positive mode. The sample cone voltage was set to 30 V, and the source temperature was 110°C. High-purity nitrogen was used as the nebulization and auxiliary gas. The nebulization gas was set to 600 L/h, the cone gas was set to 50 L/h, and the desolation temperature was 350°C. The Q-TOF Premier acquisition rate was 0.1 s, and there was a 0.02 s interscan delay. Argon, which was used as the collision gas, was maintained at a pressure of 5.3 × 10−5 Torr. The instrument was operated with the first resolving quadruple in a wide pass mode (100 Da–1500 Da). Leucineen kephalinamide acetate was used as the lock mass ([M − H]− = 553.2775, [M + H]+ = 555.2931).

2.2. Calculation and Prediction of Absorbable Components

First, we determined the structural formulas of the chemical components that were identified in compound NXT from the Chemical Book website and used the Chemdraw software to draw these formulas. Then, we imported these structural formulas into the Online SMILES Translator and Structure File Generator (http://cactus.nci.nih.gov/translate/) to obtain the smiles format. Finally, we input the smiles format of the chemical components into the Molispiration Smiles website (http://www.molinspiration.com/cgi-bin/properties) to calculate the prediction parameters of drug absorption. According to the five principles of drug absorption, if a component was subject to the following provisions of the corresponding parameters, it could be identified as an absorbable component: hydrogen bond donor (the number of hydrogen atoms attached to the O and N) nOHNH ≤ 5; relative molecular mass MW ≤ 500; fat water partition coefficient miLogP ≤ 5; and hydrogen bond acceptor (the number of O and N) nON ≤ 10.

2.3. Prediction and Screening of Targets

Using the software of Chembio3D Ultru12.0, we transformed the structure of the absorbed components into the sdf structure format. Then, to predict the possible targets, we imported the components into the public network server of the target database of the efficacy group PharmaMapper website (http://59.78.96.61/pharmmapper/) to perform reverse docking. We selected the top 10 targets for subsequent study.

2.4. Prediction and Screening of Pathways

We imported the obtained targets into the Bio database (http://bioinfo.capitalbio.com/mas3/) and then screened for pathways that met the criterion of P < 0.01.

2.5. Construction of Network

According to the screening pathways with their corresponding targets and components, we created a component-target-pathway illustration using Cytoscape. Then, according to the main selected targets, we drew a target-composition diagram.

3. Results

3.1. UPLC/Q-TOF-MS Analysis

We analysed the chemical components of NXT using ultraperformance liquid chromatography combined with quadrupole time-of-flight mass spectrometry. Because different chemical components had better responses in different modes, MS data were obtained in both positive ion mode (Figure 1(a)) and negative ion mode (Figure 1(b)). MS data in (+/−) ESI modes and the identification results for the constituents in NXT were presented in Table 2. In all 16 herbs from NXT, no related component in Myrrha and Hirudo was found.
Figure 1

UPLC/Q-TOF-MS analysis of NXT. (a) Chromatograms of NXT in positive ion mode. (b) Chromatograms of NXT in negative ion mode.

Table 2

MS data in (+/−) ESI modes and the identification results for the constituents in NXT.

Peak numberRT (min)IdentificationModeMS (m/z)CompositionHerbal source
10.647ArgininePos/Neg174.2024C6H14N4O2 PT
20.702ValinePos117.1478C5H11NO2 PT
30.721ProlinePos115.1331C5H9NO2 PT
40.776Malic acidNeg134.0911C4H6O5 RA
51.053Citric acidNeg192.1286C6H8O7 RA
61.201D-5-oxoprolineNeg129.1174C5H7NO3 RAS
71.201L-5-oxoprolineNeg129.1174C5H7NO3 RAS
81.275Succinic acidNeg118.0910C4H6O4 RAS, RAB, PT
91.294 ρ-Coumaric acidPos164.1601C9H8O3 RAS
101.310o-Phthalic acidPos166.1294C8H6O4 RAS
111.312AdenosinePos267.2403C10H13N5O4 RAS, PT, RCX
121.331LeucinePos131.1688C6H13NO2 PT
131.460IsoleucinePos131.1688C6H13NO2 RAB
141.589 Gallic acida Neg170.1207C7H6O5 RPR
152.199PhenylalaninePos165.1874C9H11NO2 FC
162.459DanshensuNeg198.1701C9H10O5 RSM
172.606Palmitic acidNeg256.3380C16H32O2 RAS, FC, RA, SCP
183.438Senkyunolide BNeg204.2374C12H12O3 RCX
193.456Senkyunolide CNeg204.2374C12H12O3 RCX
203.600Protocatechuic aldehydeNeg138.1185C7H6O3 RSM, RC
213.974Mulberroside Aa Neg568.5277C26H32O14 RM
224.122GallicinNeg184.1453C8H8O5 RPR
234.230Hydroxysafflor yellow APos/Neg612.5364C27H32O16 FC
244.2327-HydroxycoumarinPos162.1457C9H6O3 RM
254.565Vanillic acidNeg168.1459C8H8O4 RCX, RPR
264.694Benzoic acidNeg122.1209C7H6O2 RPR
274.935EpicatechinNeg290.2674C15H14O6 CS
285.157CatechinNeg290.2674C15H14O6 RPR
295.212AlbiflorinPos480.4653C23H28O11 RPR
305.730Quercetin-7-O-glucosideNeg464.3754C21H20O12 FC
315.952RutinNeg610.5203C27H30O16 RA
325.970Calycosina Neg284.2679C16H12O5 RA
335.988Calycosin-7-O-glucosidePos446.4075C22H22O10 RA
345.989Ferulic acida Neg194.1815C10H10O4 RA, RCX, RAS, RAB
356.321Paeoniflorina Pos480.466C23H28O11 RPR
366.358Pentagalloylglucosea Neg940.68C41H32O26 RPR
376.413Kaempferol-3-O-rutinosidea Pos/Neg594.5179C27H30O15 FC
386.6543,5-Di-O-caffeoylquinic acida Pos/Neg516.4573C25H24O12 CS
396.987Dicaffeoylquinic acidNeg516.1275C25H24O12 RCX
407.042Z-Butylidenephthalidea Neg188.2259C12H12O2 RCX
417.210Salvianolic acid ANeg494.4578C26H22O10 RSM
427.4494-Hydroxyl-3-butylphthalidePos206.2346C12H14O3 RCX
437.540Salvianolic acid BNeg718.6220C36H30O16 RSM
447.688OnoninPos430.4107C22H22O9 CS
457.763Senkyunolide FPos206.1017C12H14O3 RCX, RAS
467.855Salvianolic acid ENeg718.1512C36H30O16 RSM
478.243Biochanin APos/Neg284.2689C16H12O5 CS
488.262(6aR,11aR)-3-Hydroxy-9,10-dimethoxy pterocarpanPos300.3107C17H16O5 RA
498.594N1-N5-(Z)-N10-(E)-tri-p-coumaroylspermidinePos583.2703C34H37N3O6 FC
508.740BenzoylpaeoniflorinPos584.5723C30H32O12 RPR
519.518PratenseinNeg300.0679C16H12O6 RA
529.611Hydroxyl calendic acidNeg294.4342C18H30O3 SP
539.648 Trans-oxyresveratrolPos244.2435C14H12O4 RM
5410.240Formononetina Pos/Neg268.2580C16H12O4 RA
5510.405Astragaloside IVNeg784.4633C41H68O14 RA
5610.590Senkyunolide HNeg220.2305C12H12O4 RCX
5710.978Astragaloside IINeg826.4701C43H70O15 RA
5811.311Soyasaponin INeg942.5145C48H78O18 RA
5911.422Methyl tanshinonatePos338.1087C20H18O5 RSM
6011.588Carnosic acidNeg332.4311C20H28O4 RSM
6111.644Kaempferol-3-O-glucosideNeg448.3752C21H20O11 FC
6211.699Hydroxytanshinone IIAPos310.1199C19H18O4 RSM
6311.7923-Butylidene-7-hydroxyphalideNeg204.2331C12H12O3 RCX
6411.921Tanshinone II-BPos310.1187C19H18O4 RSM
6512.198Senkyunolide APos192.2516C12H16O2 RCX
6612.975Salvianolic acid FNeg314.0735C17H14O6 RSM
6713.196KumatakeninNeg314.3359C17H14O6 RA
6813.2333-n-ButylphthalidePos190.2356C12H14O2 RCX
6913.474(Z)-ligustilidea Pos190.2109C12H14O2 RAS
7013.483(E)-ligustilidea Pos190.2109C12H14O2 RAS
7113.917Trijuganone B Pos280.1107C18H16O3 RSM
7216.098Cryptotanshinonea Neg296.3642C19H20O3 RSM
7316.394Senkyunolide MPos278.1565C16H22O4 RCX
7417.503O-Phthalic anhydridePos148.0207C8H4O3 FC
7517.614Chlorogenic acida Neg354.3120C16H18O9 CS
7618.076Tanshinone IIAPos294.3430C19H18O3 RSM
7718.205AngelicidePos380.1917C24H28O4 RCX
7820.460CarthamidinPos288.2575C15H12O6 FC
7922.078Linoleic acidNeg280.2387C18H32O2 SP
8022.659Acetyl-11-keto-β-boswellic acidPos/Neg512.7458C32H48O5 FK
8122.881Oleanolic acidNeg456.3652C30H48O3 RSM

“a” refers to the component has been verified by standard substance.

3.2. Absorption Parameters of Components

Using a computer prediction method to calculate the identified compounds of NXT, we obtained absorption parameters that could determine whether the chemical compositions could be absorbed. Table 3 showed the specific absorption parameters of all of the components. The data indicated that there were a total of 63 chemical compositions (Figure 2) that met the five principles of drug absorption. As shown, 7 glycosides were identified. Although the relative molecular masses of those compounds were greater than 500, they could also be absorbed, because those compounds could be divided into two parts, including aglycones which mainly mediated drug efficacy and sugar chains in the body. So we could import these glycosides' aglycones into PharmMapper to obtain the relevant parameters. The results showed that both of these components were consistent with the five principles of drug absorption, so we considered that these 7 chemical compositions could be absorbed in the body.
Table 3

Absorption parameters of the components.

NumberCompoundsMW nON nOHNHmiLogP Results
1Arginine174.20467−3.632
2Valine117.1533−1.91
3Proline115.13232−1.723
4Malic acid134.08753−1.57
5Citric acid192.12374−1.983
6D-5-oxoproline129.11542−2.402
7L-5-oxoproline129.11542−2.402
8Succinic acid118.08842−0.655
9 ρ-Coumaric acid164.160321.43
10o-Phthalic acid166.132421.034
11Adenosine267.24595−0.854
12Leucine131.17533−1.382
13Isoleucine131.17533−1.41
14Gallic acida 170.120540.589
15Phenylalanine165.19233−1.231
16Danshensu198.17454−0.251
17Palmitic acid256.43217.059
18Senkyunolide B204.225312.81
19Senkyunolide C204.225312.574
20Protocatechuic aldehyde138.122320.759
21Mulberroside Aa 568.5281410−0.852
22Gallicin184.147530.848
23Hydroxysafflor yellow A612.541612−4.12
247-Hydroxycoumarin162.144311.511
25Vanillic acid168.148421.187
26Benzoic acid122.123211.848
27Epicatechin290.271651.369
28Catechin290.271651.369
29Albiflorin480.466115−1.636
30Quercetin-7-O-glucoside464.379128−0.104
31Rutin610.5211610−1.063
32Calycosina 284.267522.377
33Calycosin-7-O-glucoside446.4081050.59
34Ferulic acida 194.186421.249
35Paeoniflorina 480.4661150.044
36Pentagalloylglucosea 940.68126152.761
37Kaempferol-3-O-rutinosidea 594.522159−0.574
383,5-Di-O-caffeoylquinic acida 516.4551271.424
39Dicaffeoylquinic acid516.461271.21
40Z-Butylidenephthalidea 188.226203.077
41Salvianolic acid A494.4521073.014
424-Hydroxyl-3-butylphthalide206.241313.42
43Salvianolic acid B718.6201691.615
44Ononin430.409941.307
45Senkyunolide F206.24311.72
46Salvianolic acid E718.6216102.83
47Biochanin A284.267522.804
48(6aR,11aR)-3-Hydroxy-9,10-dimethoxy pterocarpan300.31512.546
49N1-N5-(Z)-N10-(E)-tri-p-coumaroylspermidine538.68954.3
50Benzoylpaeoniflorin584.5741242.472
51Pratensein300.27632.09
52Hydroxyl calendic acid294.435324.93
53Trans-Oxyresveratrol244.246442.723
54Formononetina 268.268413.095
55Astragaloside IV784.981491.21
56Senkyunolide H220.224422.314
57Astragaloside II827.021581.91
58Soyasaponin I943.1318111.7
59Methyl tanshinonate338.36500.93
60Carnosic acid332.440434.603
61Kaempferol-3-O-glucoside448.3801170.125
62Hydroxytanshinone IIA310.35413.24
633-Butylidene-7-hydroxyphthalide204.225312.81
64Tanshinone II-B310.35412.97
65Senkyunolide A192.258203.521
66Salvianolic acid F314.29652.33
67Kumatakenin314.29622.98
683-n-Butylphthalide190.242203.483
69(Z)-Ligustilidea 190.242202.927
70(E)-Ligustilidea 190.242202.927
71Trijuganone B280.32313.9
72Cryptotanshinonea 296.366303.83
73Senkyunolide M278.35412.55
74O-Phthalic anhydride148.12300.93
75Chlorogenic acida 354.31196−0.453
76Tanshinone IIA294.350304.158
77Angelicide380.48405.73
78Carthamidin288.255641.649
79Linoleic acid280.45216.86
80Acetyl-11-keto-β-boswellic acid512.73516.39
81Oleanolic acid456.71326.72

Note. “√” means that component could be absorbed; “✕” means that component could not be absorbed.

“a” refers to the component has been verified by standard substance.

Figure 2

Structures of 63 absorbable components.

3.3. Potential Targets and Pathways

By importing 63 chemical compositions that were predicted to be absorbable into the PharmMapper database for directional docking, we obtained a total of 123 targets. We then imported these targets into the Molecule Annotation System and obtained 77 pathways regulated by NXT with highly significant differences, from which we chose the top 40 pathways that met the criterion of P < 0.01 (Table 4). A total of 34 targets were related to these top 40 pathways, and HRAS, MAP2K1, and MAPK14 were associated with most of these pathways, so we considered these factors to be the main targets. As shown in Table 4, NFAT and hypertrophy of the heart (transcription in the broken heart) ranked first among these pathways.
Table 4

Top 40 Biocarta pathways regulated by NXT (P < 0.01).

RankPathwayCount P-value q-valueGene
1NFAT and hypertrophy of the heart (transcription in the broken heart)65.75E − 103.58E − 09HRAS; GSK3B; MAPK14; FKBP1A; F2; MAP2K1
2Phosphoinositides and their downstream targets51.39E − 098.47E − 09GSK3B; PDPK1; BTK; RAB5A; EEA1
3Intrinsic Prothrombin Activation Pathway48.50E − 082.82E − 07F10; FGG; F11; F2
4Bioactive Peptide Induced Signaling Pathway44.08E − 079.30E − 07HRAS; MAPK14; F2; MAP2K1
5BCR Signaling Pathway44.88E − 071.08E − 06HRAS; MAPK14; BTK; MAP2K1
6Estrogen-responsive protein Efp controls cell cycle and breast tumors growth36.40E − 071.34E − 06CDK2; ESR1; CDK6
7Nuclear receptors in lipid metabolism and toxicity48.02E − 071.58E − 06CYP2C9; VDR; NR1H3; PPARA
8Map kinase inactivation of SMRT corepressor31.53E − 062.48E − 06THRB; MAPK14; MAP2K1
9MAP Kinase Signaling Pathway52.09E − 063.05E − 06HRAS; MAPK10; MAPK14; TGFBR1; MAP2K1
10Extrinsic Prothrombin Activation Pathway32.99E − 064.05E − 06F10; FGG; F2
11 amiPathway35.17E − 066.40E − 06F10; FGG; F2
12Roles of β-arrestin-dependent recruitment of Src kinases in GPCR signaling36.57E − 067.86E − 06HRAS; HCK; MAP2K1
13Aspirin blocks signaling pathway involved in platelet activation38.19E − 069.49E − 06HRAS; F2; MAP2K1
14Insulin Signaling Pathway32.03E − 052.03E − 05HRAS; INSR; MAP2K1
15IL-2 Signaling Pathway32.37E − 052.29E − 05HRAS; MAP2K1; LCK
16Role of ERBB2 in signal transduction and oncology32.37E − 052.29E − 05HRAS; ESR1; MAP2K1
17Links between Pyk2 and MAP kinases32.74E − 052.45E − 05HRAS; MAPK14; MAP2K1
18NF-κB activation by nontypeable Hemophilus influenzae32.74E − 052.45E − 05MAPK14; TGFBR1; NR3C1
19Influence of Ras and Rho proteins on G1 to S transition33.14E − 052.82E − 05HRAS; CDK2; CDK6
20fMLP induced chemokine gene expression in HMC-1 cells33.14E − 052.82E − 05HRAS; MAPK14; MAP2K1
21Growth Hormone Signaling Pathway33.14E − 052.82E − 05HRAS; INSR; MAP2K1
22Cell cycle: G1/S checkpoint34.06E − 053.37E − 05CDK2; GSK3B; CDK6
23Fc epsilon receptor I signaling in mast cells34.58E − 053.70E − 05HRAS; BTK; MAP2K1
24Signaling of hepatocyte growth factor receptor36.40E − 054.89E − 05HRAS; MET; MAP2K1
25p38 MAPK signaling pathway37.85E − 055.76E − 05HRAS; MAPK14; TGFBR1
26Keratinocyte differentiation31.13E − 047.81E − 05HRAS; MAPK14; MAP2K1
27T cell receptor signaling pathway31.13E − 047.81E − 05HRAS; MAP2K1; LCK
28TSP-1 induced apoptosis in microvascular endothelial cell21.46E − 049.59E − 05CASP3; MAPK14
29The role of FYVE-finger proteins in vesicle transport21.46E − 049.59E − 05RAB5A; EEA1
30Mechanism of gene regulation by peroxisome proliferators via PPARa(alpha)31.82E − 041.15E − 04HSP90AA1; NR1H3; PPARA
31Visceral fat deposits and the metabolic syndrome21.95E − 041.21E − 04HSD11B1; NR3C1
32RB tumor suppressor/checkpoint signaling in response to DNA damage22.50E − 041.44E − 04CDK2; CHEK1
33Platelet Amyloid Precursor Protein Pathway22.50E − 041.44E − 04F11; F2
34Fibrinolysis Pathway23.12E − 041.77E − 04FGG; F2
35Corticosteroids and cardioprotection23.12E − 041.77E − 04HSP90AA1; NR3C1
36Phosphorylation of MEK1 by cdk5/p35 downregulates the MAP kinase pathway23.81E − 042.09E − 04HRAS; MAP2K1
37VEGF, hypoxia, and angiogenesis25.38E − 042.79E − 04HRAS; KDR
38How progesterone initiates oocyte membrane26.27E − 043.17E − 04HRAS; PGR
39IL-3 Signaling Pathway26.27E − 043.17E − 04HRAS; MAP2K1
40Sprouty regulation of tyrosine kinase signals26.27E − 043.17E − 04HRAS; MAP2K1
In Table 5, these top 40 pathways were classified into 5 categories, which included pathways associated with heart diseases and blood vessels, metabolism, cell cycle (with proliferation and apoptosis), immunity, and other pathways. By classifying these pathways, we accessed and marked the corresponding medicinal materials of NXT (Table 5). In the pathways associated with heart diseases and blood vessels, RCX, RSM, and FC were the most important. In the regulation of metabolism, RA, RSM, and RCX showed diametrical effect. All the herbs except Semen Persicae (SP) were related metabolism pathways due to the current research. RA, RSM, RCX, and FC could regulate the pathways about cell cycle, proliferation, and apoptosis. Some other important pathways were also affected by some herbs like RA, RSM, and RCX, for example, Insulin Signaling Pathway and p38 MAPK Signaling Pathway.
Table 5

The herbs of NXT involved in the top 40 pathways.

CategoryPathwayNXTRARPRRSMRASRCXSPFCCSRABRCRMPT
Pathway associated with heart diseases and blood vesselsNFAT and hypertrophy of the heart (transcription in the broken heart)1111110111111
Intrinsic Prothrombin Activation Pathway1011110100010
Extrinsic Prothrombin Activation Pathway1011110100000
Aspirin blocks signaling pathway involved in platelet activation1111110111111
TSP-1 induced apoptosis in microvascular endothelial cell1111110100000
Platelet Amyloid Precursor Protein Pathway1000010100010
Fibrinolysis Pathway1011010100100
Corticosteroids and cardioprotection1101010000010
VEGF, hypoxia, and angiogenesis1111111111111

Pathway associated with metabolismNuclear receptors in lipid metabolism and toxicity1111011101010
Growth Hormone Signaling Pathway1111110111111
Visceral fat deposits and the metabolic syndrome1101110000000

Pathway associated with immunity BCR Signaling Pathway 1111110111111
IL-2 Signaling Pathway1111110111111
fMLP induced chemokine gene expression in HMC-1 cells1111110111111
T Cell Receptor Signaling Pathway1111110111111

Pathway associated with cell cycle, proliferation, and apoptosisPhosphoinositides and their downstream targets1001010110000
Estrogen-responsive protein Efp controls cell cycle and breast tumors growth1111110010000
Map kinase inactivation of SMRT corepressor1111110100000
MAP Kinase Signaling Pathway1111110111111
Roles of β-arrestin-dependent recruitment of Src kinases in GPCR signaling1111110111111
Role of ERBB2 in signal transduction and oncology1111110111111
Links between Pyk2 and MAP kinases1111110111111
NF-κB activation by nontypeable Hemophilus influenzae 1101110100000
Influence of Ras and Rho proteins on G1 to S transition1111110111111
Cell cycle: G1/S checkpoint1111110010000
Fc epsilon receptor I signaling in mast cells1111110111111
Signaling of hepatocyte growth factor receptor1111110111111
Keratinocyte differentiation1111110111111
RB tumor Suppressor/checkpoint signaling in response to DNA damage1111110010000
IL-3 Signaling Pathway1111110111111
Sprouty regulation of tyrosine kinase signals1111110111111

Other pathwaysBioactive Peptide Induced Signaling Pathway1111110111111
amiPathway1011110100000
Insulin Signaling Pathway1111110111111
p38 MAPK Signaling Pathway1111110111111
The role of FYVE-finger proteins in vesicle transport1000000100000
Mechanism of gene regulation by peroxisome proliferators via PPARα 1101010000010
Phosphorylation of MEK1 by cdk5/p35 downregulates the MAP kinase pathway1111110111111
How progesterone initiates oocyte membrane1111111111111

Note. “1” means that the Chinese herbal medicine acts on the pathway while “0” means it does not. The pathways in each category are sorted by the significant differences in P value.

3.4. Pharmacology Network of NXT

Using the Cytoscape software, we constructed a pharmacology network of NXT (Figure 3), which showed us the relationships of the top 40 pathways, targets, and chemical components. We obtained preliminary understanding of the mechanism of NXT through this network.
Figure 3

Pharmacology network of the “components-targets-pathways” regulated by NXT.

In this research, we found three major targets of NXT: HRAS, MAP2K1, and MAPK14, which were involved in most regulated pathways. By Figure 4, based on illustration of the main targets with their corresponding compounds, we found the most effective ingredients of NXT were organic acids, saponins, and tanshinones. The main sources of organic acids were RA, RCX, RAS, and RAB. The saponins were mainly derived from RA. Meanwhile, tanshinones were mainly concentrated in RSM.
Figure 4

Network of major targets of NXT with corresponding compounds.

4. Discussion

The burden of cardiovascular and circulatory disease is becoming more and more serious, with cerebrovascular disease (CBD) and ischemic heart disease being the most serious [7]. As the causes of cardiovascular disease (CVD) and CBD are complicated, the symptoms of these diseases are also very diverse. NXT is commonly used during clinical treatment of CVD and CBD, and the effect of this drug is remarkable. Although complex traditional Chinese medicine has great significance for the treatment of complex diseases, some questions such as the material basis and the potential mechanisms remain unanswered. Our study successfully predicted absorbable chemical compositions of NXT. These constituents primarily included ferulic acid, succinic acid, astragaloside IV, and tanshinone IIA. Ferulic acid, which is derived primarily from RA, RCX, RAS, and RAB, is reported to act as an angiogenic agent that augments angiogenesis, which is critical in ischemic diseases, such as myocardial infarction and stroke [8]. Succinic acid has been demonstrated to activate Akt phosphorylation to inhibit apoptosis and necrosis caused by cardiomyocyte hypoxia/reoxygenation [9]. Previous studies demonstrated that astragaloside IV could protect the heart through NO-dependent mechanism [10]. NO has been confirmed to prevent the mitochondrial permeability transition pore from opening [11]. During early reperfusion, it can prevent the heart from reperfusion injury by inhibiting the opening of the mitochondrial permeability transition pore [12]. Tanshinone IIA also has cardioprotective effects, such as protection of cardiomyocytes from oxidative stress-triggered damage [13]. These reports were consistent with our results. In addition to active ingredients, we also successfully predicted drug targets of NXT. The major targets were HRAS, MAP2K1, and MAPK14. The HRAS gene encodes the GTPase HRas, which is an enzyme known as transforming protein p21 [14]. With the ability to increase the effects of growth factor, HRas plays an important role in regulating the growth, differentiation, and death of endothelial cells [15]. The MAP2K1 gene encodes an enzyme named dual specificity mitogen-activated protein kinase kinase 1, and MAPK14 encodes p38-α. Both of these factors are closely related to inflammation and p38-α is also associated with cardiac hypertrophy via p38 MAPK activity in the heart. In addition, p38-α has been recognized as an isoenzyme of cardiovascular importance [16]. Among the numerous identified pathways, NFAT and hypertrophy of the heart (transcription in the broken heart) were ranked first. Nuclear factor of activated T-cells (NFAT) transcription factors, which have four different isoforms, plays crucial roles in the regulation of gene expression during heart development [17]. The isoforms NFATc3 and NFATc4 are involved in hypertrophic development, while NFATc1 plays a key role in cardiac development [18]. The dephosphorylation of NFATs can promote calcineurin regulating immune response genes [19]. Via compensatory hypertrophy, the heart adapts to persistent stress conditions, but, over time, dysfunction and myocardial failure evolve [20]. Like NFAT and hypertrophy of the heart (transcription in the broken heart), most of these pathways are involved in the formation and regulation of cardiovascular disease, such as nuclear receptors in lipid metabolism and toxicity. Nuclear receptors include a superfamily of ligand-dependent transcription factors that regulate genetic networks that control cell growth, development, and metabolism. Regulating nuclear receptors is beneficial for patients with metabolic diseases, such as cardiovascular disease, due to the requirement for balance among a number of pathways for normal metabolic control [21]. These studies confirmed the validity of our study. From the above results, we also found the different significances of the total of 16 herbs in NXT. According to Chinese Pharmacopoeia 2015, the content of RA in NXT is 66 g, which is 2-3 times the content of any other herb in the whole prescription. It was reported that RA was the monarch drug of NXT and played a key role in improving the immune system, invigorating blood circulation, and the condition of myocardial ischemia and hypoxia [22]. Our study found that RA contained a lot of effective components, organic acids, and saponins and was critical source of the main active components of NXT. Through the comparison of the herbs involved in the top 40 pathways, RA was also proved to be the most important. In the top 40 pathways regulated by NXT, RA was involved in 33 pathways. Some other herbs, such as RSM, RCX, FC, and RAS, were also the important contents in the whole prescription of NXT. The network pharmacology method used in this study is a novel methodology based on the construction of multilayer networks of disease phenotype-gene-drug to predict drug targets in a holistic manner and promote efficient drug discovery [23]. This method represents a breakthrough in comparison to the traditional herbal medicine research pattern “gene-target-disease” and initiates the new pattern “multiple genes-multiple targets-complex diseases” [24]. By this method, we proved that RA was the critical ingredient mainly involved in the regulation of metabolism and immunity in NXT. RAS was a major herb that regulated cell growth. RSM, RCX, and FC also played important roles in regulation of heart disease, blood vessels, and others. The results indicated that NXT, a complex prescription in the treatment of complex diseases, played a therapeutic effect through multiple targets and multiple pathways. This was the first study to investigate the mechanism of NXT using this method, and we successfully predicted the main targets and pathways, providing a foundation for further research. This method has important value for the study of complex drugs and should be applied in future studies.

5. Conclusion

The main components that mediated the efficacy of NXT were organic acids, saponins, and tanshinones. Radix Astragali was the critical herbal medicine in NXT, which contained more active components than others and regulated more targets and pathways. NXT had a therapeutic effect on the treatment of heart diseases through the pattern “multiple components-multiple targets-multiple pathways.”
  24 in total

1.  A 500-kb physical map and contig from the Harvey ras-1 gene to the 11p telomere.

Authors:  M W Russell; D J Munroe; E Bric; D E Housman; J Dietz-Band; H C Riethman; F S Collins; L C Brody
Journal:  Genomics       Date:  1996-07-15       Impact factor: 5.736

Review 2.  Transcription factors of the NFAT family: regulation and function.

Authors:  A Rao; C Luo; P G Hogan
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 3.  [Network pharmacology: new opportunity for the modernization of traditional Chinese medicine].

Authors:  Zhi-Hua Liu; Xiao-Bo Sun
Journal:  Yao Xue Xue Bao       Date:  2012-06

Review 4.  New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

Authors:  Eva Denise Martin; Gian Felice De Nicola; Michael S Marber
Journal:  Circulation       Date:  2012-07-17       Impact factor: 29.690

5.  Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi.

Authors:  Ming-wei Huang; Huan Wang; Wen-juan Zhong; Xiao-ying Wu; Hui Chen
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2011-01

6.  Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro.

Authors:  Wei-Dong Zhang; Hong Chen; Chuan Zhang; Run-Hui Liu; Hui-Liang Li; Hong-Zhuan Chen
Journal:  Planta Med       Date:  2006-01       Impact factor: 3.352

7.  Isoform- and tissue-specific regulation of the Ca(2+)-sensitive transcription factor NFAT in cardiac myocytes and heart failure.

Authors:  Andreas Rinne; Nidhi Kapur; Jeffery D Molkentin; Steven M Pogwizd; Donald M Bers; Kathrin Banach; Lothar A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-19       Impact factor: 4.733

8.  Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1 alpha.

Authors:  Chiu-Mei Lin; Jen-Hwey Chiu; I-Hsing Wu; Bao-Wei Wang; Chun-Ming Pan; Yen-Hsu Chen
Journal:  J Nutr Biochem       Date:  2009-05-13       Impact factor: 6.048

9.  Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury.

Authors:  Derek J Hausenloy; Michael R Duchen; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2003-12-01       Impact factor: 10.787

10.  Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis.

Authors:  Jiajia Fu; Heqing Huang; Jiajun Liu; Rongbiao Pi; Jianwen Chen; Peiqing Liu
Journal:  Eur J Pharmacol       Date:  2007-04-27       Impact factor: 4.432

View more
  10 in total

1.  Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification and network pharmacology.

Authors:  A S P Pereira; M J Bester; Z Apostolides
Journal:  Mol Divers       Date:  2017-09-18       Impact factor: 2.943

2.  Naoxintong/PPARγ Signaling Inhibits Cardiac Hypertrophy via Activation of Autophagy.

Authors:  Shuping Yuan; Jianhua Jin; Lu Chen; Yongzhong Hou; Hong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-15       Impact factor: 2.629

3.  Integrated metabolomics and gut microbiome to the effects and mechanisms of naoxintong capsule on type 2 diabetes in rats.

Authors:  Zenghao Yan; Hao Wu; Haokui Zhou; Shuo Chen; Yan He; Weijian Zhang; Taobin Chen; Hongliang Yao; Weiwei Su
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

4.  Naoxintong Capsule Inhibits the Development of Cardiovascular Pathological Changes in Bama Minipig Through Improving Gut Microbiota.

Authors:  Wei-Jian Zhang; Wei-Wei Su; Pei-Bo Li; Hong-Yu Rao; Qing-Wei Lin; Xuan Zeng; Tao-Bin Chen; Zeng-Hao Yan; Hong Liu; Hong-Liang Yao
Journal:  Front Pharmacol       Date:  2019-10-03       Impact factor: 5.810

5.  Systems Pharmacology-Based Approach to Comparatively Study the Independent and Synergistic Mechanisms of Danhong Injection and Naoxintong Capsule in Ischemic Stroke Treatment.

Authors:  Junfeng Zhu; Xiaojiao Yi; Yiwen Zhang; Zongfu Pan; Like Zhong; Ping Huang
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-04       Impact factor: 2.629

6.  Evaluation of the anti-inflammatory and antioxidant pharmcodynamic compoents of naoxintong capsules as a basis of broad spectrum effects.

Authors:  Bin Lv; Lina Deng; Tian Xie; Xing Wei; Xiao Liu; Wangxiao Tan; Xiaoying Wang; Xiumei Gao
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

7.  Spectrum-Effect Relationship Analysis of Bioactive Compounds in Zanthoxylum nitidum (Roxb.) DC. by Ultra-High Performance Liquid Chromatography Mass Spectrometry Coupled With Comprehensive Filtering Approaches.

Authors:  Si-Wei Rao; Yuan-Yuan Duan; Han-Qing Pang; Shao-Hua Xu; Shou-Qian Hu; Ke-Guang Cheng; Dong Liang; Wei Shi
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

8.  Chemical Profiles and Simultaneous Quantification of Aurantii fructus by Use of HPLC-Q-TOF-MS Combined with GC-MS and HPLC Methods.

Authors:  Yingjie He; Zongkai Li; Wei Wang; Suren R Sooranna; Yiting Shi; Yun Chen; Changqiao Wu; Jianguo Zeng; Qi Tang; Hongqi Xie
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

9.  NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice.

Authors:  Shu Yang; Mengyang Liu; Yuanli Chen; Chuanrui Ma; Lipei Liu; Buchang Zhao; Yong Wang; Xiaoju Li; Yan Zhu; Xiumei Gao; Deling Kong; Yajun Duan; Jihong Han; Xiaoxiao Yang
Journal:  Sci Rep       Date:  2018-06-14       Impact factor: 4.379

10.  Protective effects of Naoxintong capsule alone and in combination with ticagrelor and atorvastatin in rats with Qi deficiency and blood stasis syndrome.

Authors:  Wei-Jian Zhang; Wei-Wei Su; Qing-Wei Lin; Yan He; Zeng-Hao Yan; Yong-Gang Wang; Pei-Bo Li; Hao Wu; Hong Liu; Hong-Liang Yao
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.